AbbVie
Discovering and Delivering Medicines
About AbbVie
Funding & Growth
✓ Pros
- • Strong revenue
- • Diverse portfolio
- • Good compensation
- • Research investment
- • Stable company
✗ Cons
- • Chicago area location
- • Humira loss of exclusivity
- • Large company processes
- • Some bureaucracy
🏢 Working Here
AbbVie operates major computational biology centers in Cambridge, MA (Kendall Square - a primary hub for early discovery and genomics), North Chicago, IL (headquarters), and South San Francisco, CA.
The Cambridge office is particularly strong in oncology, human genetics, and early target discovery, taking full advantage of Boston's exceptional biotech ecosystem and academic collaborations.
Following the 2020 Allergan acquisition, AbbVie expanded capabilities in neuroscience, aesthetics, and ophthalmology.
Bioinformaticians work on blockbuster drugs including Humira (immunology), Imbruvica (cancer), Rinvoq/Skyrizi (next-gen immunology), and the extensive Allergan portfolio.
The Boston/Cambridge location provides unmatched access to computational biology talent, academic partnerships with Harvard/MIT, and networking with other pharma companies in Kendall Square.
The company culture emphasizes patient impact and scientific excellence, with publications highly encouraged.
Work involves analyzing clinical trial data for companion diagnostics, biomarker discovery, target identification using genomics, and increasingly, neuropsychiatric disease genetics.
Each location has strengths - Cambridge for discovery and genetics, Chicago for clinical development and immunology depth, California for neuroscience and Allergan programs.
🧬 Bioinformatics Focus
AbbVie's computational efforts span immunology, oncology, and neuroscience. Key focus areas:
- Immunology biomarkers - analyzing patient samples from Rinvoq and Skyrizi trials for RA, psoriasis, Crohn's disease, understanding mechanisms of response and resistance to JAK inhibitors and IL-23 inhibitors,
- Oncology precision medicine - analyzing Imbruvica (BTK inhibitor) resistance in CLL and lymphomas, developing predictive biomarkers for venetoclax combinations,
- Neuropsychiatry genetics - identifying targets for schizophrenia, depression, Alzheimer's, Parkinson's disease using human genetics and multi-omic approaches,
- Single - cell immunology - deep profiling of immune cells in inflammatory diseases to understand disease mechanisms and drug effects,
- Patient stratification - integrating genetics, transcriptomics, and clinical data to identify patient populations most likely to benefit. The Allergan acquisition brought capabilities in neuroscience and ophthalmology. AbbVie collaborates extensively with academic medical centers and maintains partnerships for large-scale genetics studies. Technical challenges include analyzing chronic disease progression over years, integrating legacy data from Abbott/AbbVie/Allergan, and developing biomarkers for complex autoimmune conditions.
📈 Career Growth & Development
Career Paths
Scientist Track
Leadership Track
Compensation
Competitive salaries, 15-20% annual bonuses, and stock grants are offered. Midwest locations provide exceptional value given the cost of living.
Development
AbbVie invests in employee development through internal programs, external courses, and conference attendance. The company encourages publications and academic collaborations.
Mobility
Internal mobility between Chicago, Cambridge, and SF sites is possible.
Growth
The Allergan acquisition created new growth opportunities. AbbVie's focus on chronic diseases provides stable long-term career opportunities.
Expertise
Computational biologists can develop expertise in immunology or oncology. They can become recognized experts in these fields.
Network
The AbbVie alumni network includes leaders across pharma and biotech.
💊 Top Medicines & Blockbuster Drugs
Humira (adalimumab)
2002Indication: Rheumatoid arthritis, Crohn's disease, psoriasis, and 8+ autoimmune diseases
Was world's top drug - lost US exclusivity 2023
Annual Revenue (USD)
Skyrizi (risankizumab)
2019Indication: Plaque psoriasis, psoriatic arthritis, Crohn's disease
IL-23 inhibitor - fastest-growing drug
Annual Revenue (USD)
Rinvoq (upadacitinib)
2019Indication: Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, atopic dermatitis
JAK inhibitor - Humira successor
Annual Revenue (USD)
Imbruvica (ibrutinib)
2013Indication: Chronic lymphocytic leukemia (CLL), mantle cell lymphoma
BTK inhibitor - Pharmacyclics acquisition
Annual Revenue (USD)
Venclexta (venetoclax)
2016Indication: Chronic lymphocytic leukemia, acute myeloid leukemia
BCL-2 inhibitor - combination therapy
Annual Revenue (USD)